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High-density lipoprotein (HDL) is one of the major carriers of cholesterol in the blood. It attracts particular attention because, in
contrast with other lipoproteins, as many physiological functions of HDL inﬂuence the cardiovascular system in favourable ways
unless HDL is modiﬁed pathologically. The functions of HDL that have recently attracted attention include anti-inﬂammatory
and anti-oxidant activities. High anti-oxidant and anti-inﬂammatory activities of HDL are associated with protection from
cardiovascular disease. Atheroprotective activities, as well as a functional deﬁciency of HDL, ultimately depend on the protein
and lipid composition of HDL. Further, numerous epidemiological studies have shown a protective association between HDL-
cholesterol and cognitive impairment. Oxidative stress, including lipid peroxidation, has been shown to be the mediator of the
pathologiceﬀectsofnumerousriskfactorsofAlzheimer’sdisease.LifestyleinterventionsproventoincreaseHDL-cholesterollevels
including “healthy” diet, regular exercise, weight control,and smoking cessationhave also been shownto provideneuro-protective
eﬀects. This review will focus on current knowledge of the beneﬁcial eﬀects of HDL-cholesterol as it relates to cardiovascular
diseases, breast and lung cancers, non-Hodgkin’s lymphoma, as well as its neuroprotective potential in reducing the risk of
Alzheimer’s disease and dementia.
1.Introduction
1.1. Composition of HDL. Plasma high-density lipoproteins
(HDLs) are small, dense, and spherical lipid-protein com-
plexesandarenormallyconsideredtoconsistofthoseplasma
lipoprotein particles which fall into the density range of
1.063–1.210g/mL. HDL particles are composed of an outer
layer containing free cholesterol, phospholipid, and various
apolipoproteins (Apo), which covers a hydrophobic core
consisting primarily of triglycerides and cholesterol esters
[1]. The major proteins are Apo A-I (Mr 28,000) and Apo A-
II (Mr 17,000). Apo A-I, the primary protein constituent of
theseparticles,accountsforabout60%oftheproteincontent
of HDL. Apo A-I is synthesized in the intestines and liver and
is thought to be largely responsible for the antiatherogenic
eﬀects of HDL. Some HDL particles carry only Apo A-I,
whereas others contain both Apo A-I and Apo A-II [2].
Other apolipoprotein species found in HDL particles
include Apo A-IV, Apo C (C-I, C-II, and C-III), and Apo E.
Several subtypes of HDL particles have been identiﬁed on
the basis of density, electrophoretic mobility, particle size,
and apolipoprotein composition [3]. Diﬀerences in particle
size are mainly the result of the number of apolipoprotein
particles and the volume of the cholesterol ester in the core
of the particle [3].
HDL can be classiﬁed into larger, less dense HDL2 or
smaller, denser HDL3 which falls within the density ranges
1.063–1.125 and 1.125–1.210g/mL, respectively. Although
the major proportion of HDL is normally present in HDL3,
individual variability in HDL levels in human populations
usually reﬂects diﬀerent amounts of HDL2 [4]. HDL2 is
richer in particles containing Apo A-I without Apo A-II,
whereas HDL3 is richer in particles containing both Apo A-I
and Apo A-II [5].2 Cholesterol
HDL particles have multiple biological eﬀects that could
contribute to their antiatherothrombotic action including
anti-inﬂammatory,antioxidant,andproﬁbrinolyticactivities
[2]. The health beneﬁts of HDL as documented in the
literature are many. The purposes of this paper are to
review current knowledge on the beneﬁcial eﬀects of HDL-
cholesterol as it relates to (i) cardiovascular diseases, (ii)
breast and lung cancers as well as non-Hodgkin’s lymphoma,
and (iii) Alzehemier’s disease and dementia.
2.HDL-Cholesterol and
Coronary Heart Disease
2.1. Relationship between HDL-Cholesterol and Coronary
Heart Disease. Numerous prospective cohort studies
support a powerful inverse correlation between circulating
HDL-cholesterol and coronary risk among patients with
normal or elevated low-density lipoprotein- (LDL-) choles-
terol [6, 7]. Low HDL-cholesterol levels increase the risk of
coronary heart disease (CHD) and analysis of the largest
US epidemiologic studies including the Framingham Heart
Study, the Lipid Research Clinics (LRC) Primary Prevention
Trial, the LRC Prevalence Mortality Followup Study, and the
Multiple Risk Factor Intervention Trial (MRFIT) substanti-
ated that, on average, each one (1) mg/dL increase in HDL-
c h o l e s t e r o lr e d u c e sC H Dri s kb y2 %i nm e na n d3 %d e c r e a s e
in women [8].The Framingham HeartStudy havesupported
theroleoflowHDL-cholesterolasanindependentriskfactor
for coronary artery disease (CAD) and demonstrated that
subjects with the highest HDL-cholesterol levels exhibit the
lowest risk of developing CAD. Further, based on 14years of
surveillance, the Framingham Study showed that there is an
inverse relation between HDL-cholesterol and the incidence
of CAD [9]. Subsequent follow-up revealed that study
participants at the 80th percentile of HDL-cholesterol were
found to have half the risk for developing CAD when com-
pared with subjects at the 20th percentile of HDL-cholesterol
[9]. Among patients aged 50 to 80years without ischaemic
heart disease (IHD), after a mean follow-up of 4years, the
risk of myocardial infarction (MI) or IHD death decreased
by 25% for every 10mg/dL increase in HDL-cholesterol
[9].
The Israeli Ischemic Heart Disease Study examined the
CHD and all-cause mortality of some 8000 Israeli men
aged 42years and older and found that subjects with low
total cholesterol and high HDL-cholesterol had the lowest
rates of CAD-associated morbidity and mortality [10].
The Physicians’ Health Study showed that subjects with
low HDL-cholesterol had increased risk for CAD. Both
HDL-cholesterol and HDL2 levels were associated with a
substantially decreased risk of MI, but the HDL3 level was
the strongest predictor, the relative risk being 0.3 [11].
Levels of Apo A-I and Apo A-II were also associated with
decreased risk [11]. The Prospective Cardiovascular Munster
Study (PROCAM) demonstrated that subjects with HDL-
cholesterol levels ≤35mg/dL were at 3 times greater risk for
CAD compared with those who had HDL-cholesterol levels
≥35mg/dL [12].
2.2. HDL-Cholesterol as a Therapeutic Target. Reductions
in LDL-cholesterol using statins form the cornerstone of
treatment of hyperlipidemia to reduce cardiovascular mor-
bidity and mortality. Low serum concentrations of HDL-
cholesterol are one of the major risk factors for adverse
events related to coronary atherosclerosis [8] and are highly
prevalent among patients with acute coronary syndromes
[13]. Niacin is the most eﬀective therapy available for
the treatment of low HDL-cholesterol, with a nonlinear
dose-related increase in HDL-cholesterol of approximately
20% observed with modest drug doses (approximately
1g per day) [14, 15]. In the Collaborative Atorvastatin
Study Group which involved a randomized trial of the
eﬀects of atorvastatin and niacin in patients with combined
hyperlipidemiaorisolatedhypertriglyceridemia,atorvastatin
increased HDL-cholesterol by 4% and niacin by 25% [16].
The speciﬁc mechanism of action of niacin is not well
understood,butitappearstoreduceApoBsecretion,thereby
lowering both very low density lipoprotein (VLDL) and
LDL, increasing Apo A-I, and lowering lipoprotein(a) [17].
The ARBITER (Arterial Biology for the Investigation of
the Treatment Eﬀects of Reducing Cholesterol-) 2 study
examined the eﬀects of niacin added to background statin
therapyonHDL-cholesterolandcarotidintima-mediathick-
ness (CIMT), a validated surrogate cardiovascular end point
[18]. After 12months of therapy, extended-release niacin
increased HDL-cholesterol by 21% and decreased the rate of
CIMTprogression [18].Therefore,theaddition ofextended-
release niacin to statin therapy slowed the progression of
atherosclerosis among individuals with known coronary
heart disease and moderately low HDL-cholesterol [18].
In the Helsinki Heart Study and the Veterans Aﬀairs
High-Density Lipoprotein Cholesterol Intervention Trial
(VA-HIT), treatment with gemﬁbrozil was associated with
reduction in CVD events [19, 20]. The Helsinki Heart Study
examined the eﬀect of gemﬁbrozil on lipid parameters and
cardiovascular outcomes among high-risk middle-aged men
without IHD and with primary dyslipidemia [19]. After
5years of follow-up, treatment with gemﬁbrozil increased
HDL-cholesterol by 11%, decreased LDL-cholesterol and
triglycerides by 11% and 35%, respectively, and reduced
the incidence of MI and IHD death by 34%. The study
demonstrated that for every one (1) mg/dL increase in
HDL-cholesterol, the CHD risk decreased by 2% to 3%,
independent of changes in LDL-cholesterol [19]. In the VA-
HIT cohort, gemﬁbrozil was associated with a signiﬁcant
22% reduction in the risk of fatal and nonfatal CHD,
and it signiﬁcantly reduced the relative risk of investigator-
designated stroke [20]. Some evidence indicates that the
beneﬁts seen in the VA-HIT cohort may be partly due to
additional eﬀects of ﬁbrates on apolipoprotein synthesis and
lipoprotein metabolism [21, 22]. In contrast, the results
of studies using other ﬁbrates such as bezaﬁbrate and
fenoﬁbrate have been negative. Bezaﬁbrate has no eﬀect on
the incidence of CHD and of stroke combined but may
reducetheincidenceofnonfatalcoronaryevents,particularly
in those aged <65years at entry, in whom all coronary events
may also be reduced [23]. Fenoﬁbrate did not signiﬁcantly
reduce the risk of the primary outcome of coronary events;Cholesterol 3
however,itdidreducetotalcardiovascularevents,mainlydue
to fewer non-fatal MIs and revascularisations [24].
2.3. Mechanism Involved in the Beneﬁcial Eﬀects of HDL-
Cholesterol. The beneﬁcial role of HDL-cholesterol in reduc-
ing atherosclerotic disease burden is complex and likely
involves multiple mechanisms and biochemical pathways.
The primary mechanism by which HDL-cholesterol is
thought to reduce cardiovascular risk is reverse cholesterol
transport, a pathway for removing free cholesterol from
the macrophage in the arterial wall and returning it to
the liver for excretion into bile [7, 25]. HDL-cholesterol-
mediated reductions in cardiovascular risk could occur
through a variety of other pathways, including raising HDL-
cholesterol levels (by decreasing catabolism or increasing
synthesis) and having a larger number of particles available
with which to antagonize proatherogenic stimuli [26].
Collectively, HDL and its components [methionine resides
in Apo A-I,paraoxonase 1 (PON1),platelet activating factor-
(PAF-) acetylhydrolase, and other antioxidant enzymes] can
reduce oxidized lipid species in LDL particles, rendering
them less atherogenic. This may help prevent atherosclerosis,
acute coronary syndromes, and restenosis after coronary
angioplasty [27].
HDLshaveantioxidantactivitythroughtheantioxidative
properties of Apo A-I, and the presence of enzymes such
as PON1, glutathione-peroxidase, and PAF-acetylhydrolase.
Paraoxonases 1 is an HDL-associated enzyme with antiox-
idant properties. There are data suggesting that the direct
antioxidant eﬀect of HDL on LDL oxidation, measured as
a reduction in lipid peroxides, is likely mediated by PON1
[28]. Impaired PON1 activity was found to be closely linked
to increased risk of cardiovascular mortality [29]. Moreover,
PON1 activity is decreased in patients with type 2 diabetes
with [30] or without CAD [31].
HDLs seem to exert a beneﬁcial eﬀect on endothelium
function by modulating the activity and/or production
of a number of molecules [such as nitric oxide (NO),
prostacyclin (PGI2), endothelin, and PAF], and aﬀecting
vascular tone and thrombogenicity [32]. Plasma HDL-
cholesterol levels have been found to be an independent pre-
dictor of NO-dependent peripheral vasodilation in healthy
individuals [33], hyperlipidaemic and diabetic patients [34,
35], and patients with CHD [36]. Further, HDLs display
an antithrombotic eﬀect by inhibiting platelets aggregation,
reducing von Willebrand factor levels, and enhancing the
activity of activated protein C and S [37].
3. HDL-Cholesterol andRisk of Cancer
3.1. HDL-Cholesterol and Breast Cancer Risk. Boyd and
McGuire in 1990 proposed that women with high levels
of HDL-cholesterol may have an increased risk of breast
cancer [38]. This hypothesis by these authors based on the
observation that many known and suspected breast cancer
risk factors are associated with increased levels of HDL-
cholesterol, and experimental studies that suggest that HDL-
cholesterolhasaroleintheproliferationofbreasttumorcells
in vitro [39, 40]. Further, HDL-cholesterol could play a role
in carcinogenesis through its inﬂuence on cell cycle entry, via
a mitogen-activated protein kinase-dependent pathway [41]
or regulation of apoptosis [42]. Therefore, in vitro studies
that show that HDL-cholesterol promotes the growth of
breast cancer cell lines in tissue culture suggest that a direct,
causal eﬀect is biologically plausible [40, 43]. However, it is
unknown if a similar eﬀect on tumor cells occurs in vivo.
Two studies have addressed prospectively the association
of HDL-cholesterol and breast cancer incidence [44, 45].
Hoyer and Engholm investigated the association between
serum lipids and breast cancer risk in a cohort of 5,207
Danish women, who participated in The Glostrup Popula-
tion Studies between 1964 and 1986 [44]. They found an
inverse association between serum HDL-cholesterol and risk
of breast cancer, with HDL-cholesterol being signiﬁcantly
lower among women who developed breast cancer during
follow-up [44]. Gaard and colleagues in a prospective study
examined the relationship between blood lipids and breast
cancer risk in pre and postmenopausal Norwegian women.
They found no association between breast cancer risk and
blood lipids in the total population during 7 to 13years of
follow-up [45].
Several studies have reported lower levels of HDL-
cholesterol in breast cancer patients than in control subjects
[46–49]. HDL-cholesterol levels were found to be signiﬁ-
cantlylowerinpre-andpostmenopausalwomenwithbenign
and malignant breast disease [46]. Kokoglu et al. reported
signiﬁcant increase in triglycerides and VLDL-cholesterol
and decrease in HDL- and LDL-cholesterol levels in patients
with stage IV disease when compared to those with stage I
breast cancer [47]. A decrease in HDL-cholesterol, especially
in the HDL2 subfraction, was observed in newly diagnosed
breast cancer patients. Besides, HDL particle from these
patients showed increased Apo A-I/HDL-cholesterol ratio
[47]. Further, there are several reports that have shown that
tumor progression from localized to metastatic disease is
associated with declining HDL-cholesterol levels [43, 47].
Two population-based screening surveys involving Nor-
wegian women found that low HDL-cholesterol, as part
of the metabolic syndrome, is associated with increased
post-menopausal breast cancer risk, and HDL-cholesterol
association was conﬁned to women in the heavier subgroup
with body mass index (BMI) ≥25kg/m2 [50]. The risk of
post-menopausal breast cancer among overweight and obese
women in the highest serum HDL-cholesterol quartile was
one-third the risk of women in the lowest serum HDL-
cholesterol quartile. According to the authors, these ﬁndings
suggest an interaction between metabolic disturbances (i.e.,
overweight or obesity and low-serum HDL-cholesterol) in
postmenopausal breast carcinogenesis [50]. In a nested case-
control study by Moorman et al., there was a positive
association between HDL-cholesterol in serum stored for
more than 20years and postmenopausal breast cancer risk.
Further, an inverse association with premenopausal breast
cancer risk was observed [51].
3.2. HDL-Cholesterol and Lung Cancer Risk. Cancer patients
often present altered serum lipid proﬁle including changes
of HDL-cholesterol level. Case-control studies of newly4 Cholesterol
diagnosed lung cancer have shown that HDL-cholesterol
levels are reduced in lung cancer cases relative to levels
observed in the control groups [52–55]. Siemianowicz et al.
evaluated serum level of HDL-cholesterol in patients with
squamous cell and small cell lung cancer and its dependence
on histological type and clinical stage of lung cancer. They
found that there were no statistically signiﬁcant diﬀerences
of HDL-cholesterol level between the histological types or
between clinical stages of each histological type of lung
cancer [52]. Decreased serum HDL-cholesterol was also
reported in advanced nonresectable lung cancer patients
[53]. Kucharska-Newton et al. examined prospectively the
association of baseline plasma HDL-cholesterol levels with
incidence of lung cancer in subject of the Atherosclerosis
Risk in Communities (ARIC) cohort. They found relatively
weak inverse association of HDL-cholesterol with lung
cancer that was dependent on smoking status, even after
exclusion of cases diagnosed within 5years of baseline [56].
In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention
(ATBC) Study cohort, higher HDL-cholesterol levels were
related to modestly decreased risk of cancer overall; this
association remained after excluding cases diagnosed during
the ﬁrst 15years of follow-up [57].
Biological mechanisms that might link low plasma levels
of HDL-cholesterol with cancer are not well understood [38,
55]. The function of HDL-cholesterol in reverse cholesterol
transport is important in development of atherosclerosis;
however, it is not obvious how this function of HDL-
cholesterol could inﬂuence carcinogenesis [58]. Further,
HDL regulation of cell cycle entry through a mitogen acti-
vated protein kinase-dependent pathway [41] and apoptosis
[42], modulation of cytokine production, and antioxida-
tive function [59] has been considered and is biologically
plausible. The association between higher HDL-cholesterol
and lower overall cancer incidence observed in the ATBC
cohort is biologically plausible, as HDL- cholesterol has anti-
inﬂammatory properties [59]. However, it is also plausible
that this association reﬂects the eﬀect of factors that are asso-
ciated with both HDL-cholesterol and risk of cancer, such as
inﬂammation. Inﬂammation reduces HDL-cholesterol [60]
and likely increases risk of lung cancer [61].
3.3. HDL and Lymphoma Risk. Lipoprotein abnormalities
seen in patients with inﬂammatory diseases are thought
to develop secondary to circulating cytokines and the
accompanying acute-phase response. Lymphoma patients
often exhibit abnormal lipid metabolism. Clinical studies of
lymphoma patients have reported lipid abnormalities that
aresimilartothedyslipidemiaobservedininﬂammatoryand
infectious diseases [62, 63]. Further, a decrease in circulat-
ing HDL-cholesterol may occur during lymphomagenesis,
reﬂecting underlying etiology such as inﬂammation.
Spiegel et al. investigated plasma lipids and lipoproteins
at presentations in 25 patients with acute leukemia and non-
Hodgkin’s lymphoma (NHL). They found that all patients
demonstrated an abnormality in at least one plasma lipid
fraction and most exhibited a predictable pattern of lipid
alterations that consisted of extremely low levels of HDL-
cholesterol, elevated triglyceride, and elevated VLDL [62].
The degree of lipid abnormality was directly related to the
underlying tumor burden and particularly to the presence of
bone marrow involvement [62].
ToevaluatetheetiologicinvolvementofHDL-cholesterol
in lymphomagenesis, Lim et al. investigated the association
between prediagnostic serum HDL-cholesterol levels and
the subsequent development of NHL during 17years of
follow-up of Finnish male smokers in the Alpha-Tocopherol
Beta-Carotene (ATBC) Cancer Prevention Study cohort
[64]. They observed an inverse association between HDL-
cholesterol and NHL, which changed with length of follow-
up. High HDL-cholesterol was associated with lower risk of
all NHLs during the ﬁrst 10years, but not with diagnoses
during later follow-up [64]. Therefore, low circulating levels
of HDL-cholesterol in lymphoma patients may occur before
the clinical onset of cancer and may serve as a marker
for inﬂammation-induced lymphomagenesis, rather than a
consequence of lymphoma-induced acute-phase responses
[63].
Studies have shown that chronic inﬂammation is known
to reduce both serum HDL-cholesterol levels and its anti-
inﬂammatory properties [65, 66]. Low HDL-cholesterol,
therefore, may be a marker for the severity of systemic
inﬂammation and inﬂammation-induced NHL risk. Con-
versely, high HDL-cholesterol itself may be protective
against NHL. High-density lipoprotein-cholesterol seems
to modulate inﬂammatory responses independent of non-
HDL cholesterol levels [32] by suppressing chemotactic
activity of monocytes and lymphocytes [67, 68] and inhibit-
ing cytokine-induced expression of endothelial cell adhe-
sion molecules. Further, HDL-cholesterol may protect the
integrity of lymphocytes from oxidative damage [25, 69].
4.HDLP r o t ectsth eA gingB rain
4.1. HDL, Alzheimer’s Disease and Dementia. Over the
past decade, abnormalities in brain lipid metabolism are
increasingly recognized to be intimately related to the
pathogenesis of such major neurodegenerative disorders as
Alzheimer’s disease (AD) and vascular dementia (VD). With
respective frequencies of 70% and 15% of all dementias,
AD and VD are the most common forms of dementia
which are typically preceded by less dramatic cognitive
decline, including decline in memory [70]. Both AD and
atherosclerosis develop in parallel with the aging process
and as such share a number of risk factors, including the
presence of type 2 diabetes and elevated levels of total
cholesterolandLp(a)inmidlife,therebysuggestingcommon
pathophysiological pathways [71].
Cerebrovascular and Alzheimer’s pathological changes
frequently coincide in cases of dementia and may act syn-
ergistically in producing cognitive decline [72]. Lipoproteins
such as HDL may inﬂuence neurodegeneration as a carrier
of cholesterol. The extracellular deposition of amyloid beta
(Aβ) in senile plaques constitutes one of the deﬁning
hallmarks of AD. There is evidence that brain cholesterol
is related to amyloid metabolism in the brain and that
disruption of cholesterol homeostasis in AD is linked to Aβ
pathology [73]. Amyloid beta binds to HDL, maintainingCholesterol 5
its solubility in cerebrospinal ﬂuid (CSF) and plasma. This
HDL-Aβ interaction prevents the deposition of Aβ into the
brainandcanserveasamarkerforneurodegenerativedisease
[74].
Oxidative stress, including lipid peroxidation, has been
shown to be the mediator of the pathologic eﬀects of
numerous risk factors of AD [75]. Lifestyle interventions
proven to increase HDL-cholesterol levels [76] including
“healthy” diet, regular exercise, weight control, and smoking
cessation have also been shown to provide neuroprotective
eﬀects [77, 78]. Moreover, elevated HDL-cholesterol levels
potentially mediated by low cholesterol ester transfer protein
(CETP) activity are also associated with longevity, improved
cognition, and dementia-free survival [79]. Since HDL is the
lipoprotein responsible for the eﬄux of cholesterol within
cellsofthebrain,itmaybethatdeﬁcientlevelsordysfunction
of HDL-cholesterol may contribute to certain tauopathies or
dysgenesis of synaptic processes, such that individuals with
dyslipidemia may be more susceptible to neurodegenerative
disease.
Singh-Manoux et al. in The Whitehall II Study examined
the relationship between fasting serum lipids and short-
term verbal memory in middle-aged adults. They found
that low HDL-cholesterol and decreasing levels over a 5-year
follow-up period were associated with poor memory and
decline in memory, respectively, [80]. Further, according to
these authors, there are complex and variable biochemical
mechanisms potentially linking HDL to AD. The diﬀer-
ent neuroprotective properties of HDL include accelerated
maturation of synapses, maintenance of synaptic plastic-
ity, improved metabolism of Aβ, increase in hippocampal
volume, and anti-inﬂammatory and antioxidative activities
[80]. Further, brain HDL can suppress Aβ production by
decreasing cellular cholesterol through the activation of
reverse cholesterol transport mediated by ABC transporters
[81]. HDL can directly bind excess Aβ and thereby inhibit
its oligomerisation [82]. Oligomerisation represents a major
step in the transformation of the monomeric nontoxic
peptide to the aggregated neurotoxic form that can account
formemory impairment [83].HDLmayalsoremoveAβ that
accumulates in the vessel wall during the course of VD; by
analogywithreversecholesteroltransport,suchaprocesscan
be termed “reverse amyloid transport” [84]. In decreasing
oxidative stress, HDL directly decreased Aβ production, as
oxidative stress induces enhanced production of Aβ as a
potentiallyprotectiveresponse[85].Further,HDLcanacton
astrocytes to attenuate a local inﬂammatory reaction.
High-density lipoprotein particles traﬃc cholesterol in
the brain and are related to cholesterol metabolism, which
mayplayanimportantroleinAβmetabolismanddeposition
in the brain [86]. HDL-cholesterol is critical for the matura-
tion of synapses and the maintenance of synaptic plasticity
[87]. High-density lipoprotein-cholesterol has been found to
be associated with hippocampal volume and dementia [88].
Next to AD, VD is the second most common form
of dementia in the elderly, yet few speciﬁc risk factors
have been identiﬁed. Dementia occurs late in life, but it is
increasingly recognized that there is a long preclinical phase
characterized by progressive neuropathological changes that
become clinically detectable later. The “life-long” view of
dementia stresses the importance of vascular risk factors
in midlife [89]. Diﬀerent studies have investigated the
relationship between lipid levels and the risk of VD. Many
of them found an association with decreased levels of HDL-
cholesterol. Zuliani et al. found in a cross-sectional study
that low HDL-cholesterol levels are associated with VD, but
n o tw i t hl a t e - o n s e tA Di nas a m p l eo f6 0o l d e rs u b j e c t s
with VD compared with 54 controls [90]. Kuriyama et al.
reported lower HDL-cholesterol levels in 44 patients with
sporadic late-onset AD and 43 patients with VD compared
with controls [91]. The Apo A-II level was disproportionally
decreased in the patient groups. Further, the authors found
that serum Apo A-II may involve the pathological process
in the patients with senile dementia [91]. Muckle and Roy
found signiﬁcantly lower HDL-cholesterol levels in 5 men
with multi-infarct dementia than in 12 men with senile
dementia of the Alzheimer type [92].
In a population-based study involving 561 subjects
85years old, Mini-Mental State Examination (MMSE)
scores were signiﬁcantly lower in subjects with low HDL-
cholesterol. Further, in a comparison of subjects with low
HDL-cholesterol with subjects with high HDL- cholesterol,
the odds ratio for dementia was 2.3. Thus, low HDL-
cholesterol is associated with cognitive impairment and
dementia [93]. In the Northern Manhattan Stroke Study,
Sacco et al. found that high HDL-cholesterol levels were
related to a lower risk of stroke [94]. Increased HDL-
cholesterol levels were associated with reduced risk of
ischemic stroke in the elderly and among diﬀerent racial
or ethnic groups. This supports HDL-cholesterol as an
important modiﬁable stroke risk factor [94].
However, most longitudinal studies have failed to detect
similar associations; HDL-cholesterol levels have not been
associated with AD [95–97], vascular dementia [96, 97], or
dementia [97]. Romas et al. found no association between
HDL and either prevalent or incident AD [95]. In a
prospective community-based cohort study of white,African
American, and Caribbean Hispanic elderly, Reitz et al. found
a weak relation between HDL-cholesterol levels and the risk
of VD [96]. Further, in a population-based cohort study,
there was no association between HDL-cholesterol in late
life and subsequent risk of AD or dementia [97]. A possible
explanation for the contradictory ﬁndings in the literature
is that lipid levels tend to change as people become older
[98]. This pattern can be partly explained by physiologic
aging, unintentional or voluntary changes in lifestyle (due
to increased public health awareness and initiation of
interventional programs meant to lower cholesterol levels),
selective mortality, or clinical-subclinical disease [99].
Another possible explanation for the conﬂicting
epidemiologic associations between HDL-cholesterol and
dementia is that other constituents of HDL-cholesterol such
as Apo A-I may be more biologically relevant in AD or VD
pathology and may therefore represent a more accurate
dementia risk factor. In a case-control study of 45 AD
patients and 79 controls, levels of Apo A-I were lower in
Japanese patients with late-onset nonfamilial AD [100].
T h er e d u c t i o n si nA p oA - Il e v e l sw e r eo b s e r v e di nb o t h6 Cholesterol
carriers and noncarriers of the e4 allele [100]. Also, in a
case-control study of 98 AD patients and 59 elderly controls,
serum Apo A-I levels were signiﬁcantly lower in AD patients
[101]. An Apo A-I cutoﬀ value of 1.50g/L could distinguish
between the two groups with a sensitivity of 71 percent and a
speciﬁcityof69percent.ApoA-Ilevelswerehighlycorrelated
with MMSE scores and were signiﬁcantly and consistently
lower in AD patients, independent of e4 status [101]. In a
population sample of Japanese-American men, lower Apo
A-I levels were associated with increased dementia risk more
than a decade later. The associations seemed similar for AD
and VD and were present over and above adjustments for
HDL cholesterol and triglyceride levels [102].
5. Conclusion
It is clearly established that low HDL-cholesterol levels are
a major independent risk factor for CVD. Further, large
cohort studies have identiﬁed HDL-cholesterol as a strong,
independent, and inverse predictor of risk of CHD. The
recent advances in understanding the mechanisms by which
HDL acts to reduce cholesterol content in vessel walls have
suggested a number of therapeutic strategies for reducing
CHD risk by augmenting this activity. Currently available
drugs that act to increase HDL-cholesterol concentrations
include the statins, ﬁbrates, and niacin. However, although
studies such as the Collaborative Atorvastatin Study Group,
the ARBITER-2 study, the Helsinki Heart Study, and the
VA-HIT provide circumstantial evidence that therapeutic
intervention results in the elevation of HDL-cholesterol
which translates into beneﬁcial outcomes such as reduced
CVD risk, this is not deﬁnitive.
Studies have suggested an association between high
HDL-cholesterol levels and the epidemiology of breast and
lung cancer risk. High HDL-cholesterol is associated with
low risk of developing NHL in a dose-responsive manner.
Further studies on the potential role of HDL-cholesterol as
an early indicator or even as an etiologic factor of these
cancers will be of substantial importance to public health
considering the high prevalence of low HDL-cholesterol in
developed and developing countries.
Low HDL-cholesterol is common in adults and con-
tributes to high rates of cardiovascular disease and may be
linked to subsequent neurodegenerative and neurovascular
diseases. Numerous epidemiological studies have shown a
protective association between HDL-cholesterol and cogni-
tiveimpairmentanddementia.Thereareanumberofstudies
that have shown an association between low levels of HDL-
cholesterol and the risk of AD and VD. Therefore, the modu-
lation of HDL function and its concentrations in serum will
signiﬁcantly impact future approaches to the management
of cardiovascular diseases, cancers, and neurodegenerative
and neurovascular diseases such as AD and VD in both the
primary and secondary prevention settings.
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